[Growth hormone therapy in dysmorphic syndromes and chronic disease]

[Growth hormone therapy in dysmorphic syndromes and chronic disease] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Growth hormone therapy in dysmorphic syndromes and chronic disease] Abstract Text:

B J Otten,J M Wit,

Many clinical syndromes are associated with short stature, which can be proportionate or disproportionate. In the first group of syndromes, such as Turner syndrome and its variants, Down syndrome, Prader-Willi-Labhart syndrome, Noonan syndrome, and Silver-Russell syndrome growth hormone therapy can lead to increased growth velocity, but so far only short-term results have been reported. Growth hormone is contraindicated in syndromes with an increased risk of chromosomal breakage, e.g. Bloom syndrome. In disproportionate syndromes, such as hypochondroplasia, pseudopseudohypoparathyroidism, spina bifida, and hypophosphataemic rickets, the results of growth hormone therapy are not encouraging. Growth hormone therapy in children with rheumatoid arthritis and thalassaemia appears little effective. Long-term clinical trials of reasonable size are needed before reliable conclusions can be drawn about the value of growth hormone therapy in these conditions.

[Growth hormone therapy in dysmorphic syndromes and chronic disease] Publishing Authors By Initials

BJ Otten,JM Wit,

For similar pathological conditions, signs and symptoms: pathologic processes: disease: syndrome research abstracts see: pathological conditions, signs and symptoms: pathologic processes: disease: syndrome research

PUBMED ID PMID:

MEDLINE DATE:

[Growth hormone therapy in dysmorphic syndromes and chronic disease] Journal Published:

PUBLICATION TYPE: Review

Journal: Tijdschrift voor kindergeneeskunde

VOLUME: 60

Page Numbers: 183-91

Journal Abbreviation: Tijdschr Kindergeneeskd

ISSN: 0376-7442

DAY: 24

MONTH: Oct

YEAR: 1992

[Growth hormone therapy in dysmorphic syndromes and chronic disease] Information

Number of References: 35

LANGUAGE: dut

NlmUniqueID: 7704039

[Growth hormone therapy in dysmorphic syndromes and chronic disease] Keywords Mesh Terms:

KEYWORDS: Syndrome

MESH TERMS: drug therapy

Chemical & Substance for Abstract: [Growth hormone therapy in dysmorphic syndromes and chronic disease] Information

Substance Name:

Registry Number:

Grant and Affiliation Information for [Growth hormone therapy in dysmorphic syndromes and chronic disease]

AFFILIATION: Afd. Kindergeneeskunde, Academisch Ziekenhuis Nijmegen, St. Radboud.

Country: NETHERLANDS

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Tijdschr Kindergeneeskd

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Growth hormone therapy in dysmorphic syndromes and chronic disease Related Publications

• CALIPER: individualized-growth curves for the monitoring of children's growth.
• Cochlear aqueduct flow resistance depends on round window membrane position in guinea pigs.
• Debate on the use of growth hormone in the treatment of children with idiopathic short stature (ISS) (Pro and Con).
• Genetic disorders in the GH IGF-I axis in mouse and man.
• Growth hormone (GH) secretion and response to GH therapy after total body irradiation and haematopoietic stem cell transplantation during childhood.
• Height gain with combined growth hormone and gonadotropin-releasing hormone analog therapy in two pubertal siblings with a growth hormone-releasing hormone receptor mutation.
• Heterogeneous gap junction remodeling in reentrant circuits in the epicardial border zone of the healing canine infarct.
• Is there a role for remodeled connexins in AF? No simple answers.
• Meeting Report:The 7th ESPE Growth Plate Working Group Symposium - EUROGROP June 27th 2007, Helsinki, Finland.
• Morphology and function of Bast's valve: additional insight in its functioning using 3D-reconstruction.
• Post-normalization quality assessment visualization of microarray data.
• Radiographic evaluation of children with growth disorders.
• Recent advances in electrophysiology of antiarrhythmic drugs.
• Referral patterns between the child health service, general practitioners, and secondary healthcare: A prospective descriptive study in the Netherlands.
• Single gene mutations causing SGA.
• Successful Long-Term Growth Hormone Therapy in a Girl with Haploinsufficiency of the Insulin-Like Growth Factor-I Receptor due to a Terminal 15q26.2->qter Deletion Detected by Multiplex Ligation Probe Amplification.
• The 23K variant of the R23K polymorphism in the glucocorticoid receptor gene protects against postnatal growth failure and insulin resistance after preterm birth.
• The 7th ESPE Growth Plate Working Group symposium--EUROGROP, June 27th 2007, Helsinki, Finland.
• The diagnostic work up of growth failure in secondary health care; an evaluation of consensus guidelines.
• [Current developments in the treatment of growth delay using growth hormone]
• [Growth diagrams for patient care]
• [Growth hormone therapy in dysmorphic syndromes and chronic disease]
• [Growth hormone treatment in short stature of unknown origin]
• [Historical perspective on growth hormone treatment in children]
• [Results of growth hormone treatment in slow-growing children with normal plasma growth hormone levels in provocation tests]
• [Taller with growth hormones?]
• [Turner syndrome: a virtually certain indication for growth hormone treatment]